Rome – The protection induced by the anti Covid-19 vaccines is “protracted over time”, although at the moment it is not possible to quantify this duration. The most recent data suggests it, for a period between 105 and 112 days from the first dose of the vaccine, contained in the second report of the working group “Covid-19 vaccine surveillance” of the Istituto Superiore di Sanità (Iss) and the Ministry of Health.
The report updates that of 15 May and is also the result of the joint analysis of the data from the national vaccine registry and the integrated Covid-19 surveillance.
“From 105-112 days after vaccination – we read – there is a further reduction in the risk of diagnosis, with a similar effect in men, women and people in different age groups”. The data confirm those found in the first report, relating to 13.7 million people vaccinated, with the risk of death decreasing by 95% and the reduction in the risk of being diagnosed and hospitalized by 80% and 90%, respectively. The new report, referring to about 14 million people vaccinated with at least one dose, comes to an assessment over 130 days after the first dose was administered. Compared to the previous report, in the population studied there was an increase in vaccinated subjects in the age group 40 years and over and there was an increase in vaccinations with Comirnaty (Pfizer / BioNTech) and Vaxzevria (AstraZeneca) and the start of administration of the Janssen vaccine (Johnson&Johnson). Neither the results relating to each vaccine nor to the two types used up to now (based on messenger RNA and viral vector) are available as “the vaccines were introduced in successive phases and administered to populations with different risk profiles”.
In order to have more solid and comparable results, it is therefore “necessary to wait for a longer follow-up time”. The analysis confirms that “the risks of SarsCoV2 infection, hospitalization, admission to intensive care and death decrease rapidly after the first two weeks and up to about 35 days after the administration of the first dose”. After 35 days, the report continues, “a stabilization of this reduction is observed, which is about 80% for the risk of diagnosis, 90% for the risk of hospitalization and admission to intensive care and 95% for the risk of deathThe observed effects are also “similar in both men and women and in people of different age groups” and the reductions in hospitalizations are “similar” for healthcare workers and RSA guests.